Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 281

    1.

    Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease.

    Gattenlohner S, Ertl G, Einsele H, Kircher S, Muller-Hermelink HK, Marx A.

    Ann Intern Med. 2008 Jul 1;149(1):69-71. No abstract available. PMID: 18591647 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

    Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

    Cancer. 2006 Nov 1;107(9):2206-11.PMID: 16998940 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.

    Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, Guardascione MA, Margaglione M.

    Blood Coagul Fibrinolysis. 2008 Jul;19(5):459-62.PMID: 18600100 [PubMed - indexed for MEDLINE]Related articles

    4.

    Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.

    Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M.

    Blood. 2008 Feb 1;111(3):1686-9. Epub 2007 Nov 5.PMID: 17984312 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.

    Xiao Z, Zhang Y, Li L, Nie L, Yang L, Xu S.

    Haematologica. 2008 May;93(5):787-8. No abstract available. PMID: 18450736 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.

    Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A, Ritis K, Korantzis I.

    Leuk Res. 2007 Aug;31(8):1053-62. Epub 2006 Oct 12.PMID: 17045648 [PubMed - indexed for MEDLINE]Related articles

    7.

    Absence of the JAK2 V617F mutation in patients with arterial thrombosis without overt myeloproliferative disease.

    Smalberg JH, De Maat MP, Leebeek FW.

    J Thromb Haemost. 2008 Sep;6(9):1606-7. Epub 2008 Jul 12. No abstract available. PMID: 18638010 [PubMed - indexed for MEDLINE]Related articles

    8.

    Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.

    Lieu CH, Wu HS, Hon YC, Tsai WH, Yang CF, Wang CC, Lin YC, Shih CH, Hsu HC.

    Intern Med J. 2008 Jun;38(6):422-6. Epub 2008 Mar 7.PMID: 18336541 [PubMed - indexed for MEDLINE]Related articles

    9.

    JAK2 V617F: implications for thrombosis in myeloproliferative diseases.

    Hexner EO.

    Curr Opin Hematol. 2007 Sep;14(5):450-4. Review.PMID: 17934351 [PubMed - indexed for MEDLINE]Related articles

    10.

    [JAK2 mutation in myeloproliferative disorders]

    Inokuchi K.

    Rinsho Ketsueki. 2006 Aug;47(8):693-700. Review. Japanese. No abstract available. PMID: 16986707 [PubMed - indexed for MEDLINE]Related articles

    11.

    Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

    Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC.

    Blood. 2007 Jul 1;110(1):375-9. Epub 2007 Mar 15.PMID: 17363731 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).

    Hermouet S, Dobo I, Lippert E, Boursier MC, Ergand L, Perrault-Hu F, Pineau D.

    Leukemia. 2007 May;21(5):1128-30. Epub 2007 Feb 15. No abstract available. PMID: 17301814 [PubMed - indexed for MEDLINE]Related articles

    13.

    JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.

    Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N.

    Br J Haematol. 2007 Oct;139(1):64-9.PMID: 17854308 [PubMed - indexed for MEDLINE]Related articles

    14.

    Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.

    Ali FR, Roberts LN, Mistry H, Patel RK, Edmondson RA, Arya R.

    J Vasc Surg. 2009 Jan;49(1):211-3.PMID: 19174256 [PubMed - indexed for MEDLINE]Related articles

    15.

    The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.

    De Stefano V, Rossi E, Za T, Chiusolo P, Leone G.

    Thromb Haemost. 2008 Jun;99(6):1121. No abstract available. PMID: 18521519 [PubMed - indexed for MEDLINE]Related articles

    16.

    Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.

    Larsen TS, Pallisgaard N, de Stricker K, Møller MB, Hasselbalch HC.

    Hematology. 2009 Feb;14(1):11-5.PMID: 19154659 [PubMed - indexed for MEDLINE]Related articles

    17.

    Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

    Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdilès MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR.

    Blood. 2006 Nov 15;108(10):3548-55. Epub 2006 Jul 27.PMID: 16873677 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.

    Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH.

    Leukemia. 2007 May;21(5):1097-9. Epub 2007 Feb 22. No abstract available. PMID: 17315023 [PubMed - indexed for MEDLINE]Related articles

    19.

    JAK2 (V617F) mutation in healthy individuals.

    Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M.

    Br J Haematol. 2007 Feb;136(4):678-9. No abstract available. PMID: 17223913 [PubMed - indexed for MEDLINE]Related articles

    20.

    Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.

    Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S.

    Leukemia. 2008 Jun;22(6):1295-8. Epub 2007 Dec 6. No abstract available. PMID: 18059483 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data